Crescent Biopharma, Inc. (NASDAQ: CBIO) is a Healthcare company (Biotechnology) with a market capitalization of $507M. The Maz Rating grades it against the other companies in its sector.
Crescent Biopharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $13.04, Crescent Biopharma, Inc. trades at 33.9x sales and 1.9x book value. Over the last twelve months it generated about $15M of revenue and a net loss of $274M. It runs a gross margin of 99.6%, an operating margin of -1216.6% and a net margin of -1174.0%. It shows return on equity of -85.4%, return on invested capital of -65.9% and a free cash flow yield of -31.6%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 12.57. Over the past 52 weeks the share price ranged from $8.72 to $27.41, with a beta of 1.39.
Crescent Biopharma, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 10 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Crescent Biopharma, Inc. (CBIO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.51% / 30% · (Cash+Inv) / Mkt Cap (36m) 60.2% / 30% · Interest income / Revenue 70.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.51% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 60.2% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 70.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.51% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 60.2% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 70.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.27% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 93.7% / 33.33% · Receivables / Avg Assets (4Q) 1.95% / 33.33% · Interest income / Revenue 70.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.82% / 33.33% · (Cash+ST Inv) / Total Assets 96.6% / 33.33% · (Cash+Recv) / Total Assets 96.6% / 33.33% · Interest income / Revenue 70.0% / 5% | Fail |
No. As of September 2026, Crescent Biopharma, Inc. (CBIO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Crescent Biopharma, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 70.0% of each dividend: Crescent Biopharma, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.